| Drug General Information |
| Drug ID |
D0S2BV
|
| Former ID |
DNC000694
|
| Drug Name |
Glitazone
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 4 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H9NO3S
|
| CAS Number |
CAS 2295-31-0
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor gamma |
Target Info |
Agonist |
[2]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
AMPK signaling pathway
|
|
Osteoclast differentiation
|
|
Huntington's disease
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Thyroid cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Signaling events mediated by HDAC Class I
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
PPARA activates gene expression
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Wnt Signaling Pathway Netpath
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Differentiation of white and brown adipocyte
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Adipogenesis
|
|
SREBP signalling
|
|
Nuclear Receptors
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00953498) Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins. U.S. National Institutes of Health. |
|---|
| REF 2 | Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. |
|---|
